Express Pharma

Honeywell teams with AstraZeneca to develop next-generation respiratory inhalers

AstraZeneca is working to incorporate Honeywell's Solstice Air (HFO-1234ze cGMP) technology as a medical propellant, reducing the greenhouse gas emissions of the pMDIs by up to 99.9 per cent

0 234

Honeywell yesterday announced a commercial partnership with AstraZeneca to develop and bring to market next-generation respiratory inhalers that use near-zero Global Warming Potential (GWP) propellants to treat asthma and Chronic Obstructive Pulmonary Disease (COPD), Honeywell notified in a statement.

AstraZeneca is working to incorporate Honeywell’s Solstice Air (HFO-1234ze cGMP) technology as a medical propellant, reducing the greenhouse gas emissions of the pMDIs by up to 99.9 per cent when compared to current inhaler propellants. Solstice Air is the only non-flammable, near-zero GWP propellant available and in clinical development today for pMDIs, the statement added.

It also said that a recently completed phase-I clinical trial of the propellant HFO-1234ze in a pMDI containing budesonide, glycopyrronium, formoterol fumarate in healthy adults was positive, demonstrating similar safety and tolerability profile and systemic exposure of the active ingredients when compared to Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate). AstraZeneca expects Breztri Aerosphere to be the first medicine to transition to the next-generation pMDI platform, subject to regulatory approval.

Following these positive results from the phase-I trial, AstraZeneca will advance a commercial partnership with Honeywell to develop